Search
6-diazo-5-oxo-L-norleucine
go.drugbank.com/drugs/DB17537Investigational6-diazo-5-oxo-L-norleucine is a broad-acting glutamine antagonist.
PLX51107
go.drugbank.com/drugs/DB17543InvestigationalPLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.
Timdarpacept
go.drugbank.com/drugs/DB17544InvestigationalIMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. … [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.
Anzurstobart
go.drugbank.com/drugs/DB17547InvestigationalAnzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.
PF-04856884
go.drugbank.com/drugs/DB17550InvestigationalPF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor.
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalPucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.
Polyvalent antigen-KLH conjugate vaccine
go.drugbank.com/drugs/DB17565InvestigationalPolyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant
Emprumapimod
go.drugbank.com/drugs/DB17603InvestigationalEmprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Ammonium tetrathiomolybdate
go.drugbank.com/drugs/DB17641InvestigationalCategories: Compounds used in a research, industrial, or household setting